blogM3P and the Blind Spot in Prescription Cost Management: What Health Plans Still Can’t See
If you believe the Medicare Prescription Payment Plan underperformed because beneficiaries were confused, you are misdiagnosing the problem.
Confusion explains individual behavior but cannot explain system performance at scale. The more consequential issue is that most health plans lack an operational view of where prescription cost exposure concentrates and how quickly it escalates. Many discover its scale and uneven distribution only after utilization and outcomes have already shifted.
M3P did not create that gap. It revealed it.
The Pharmacy Counter: Where Financial, Clinical, and Operational Risk Converge
Prescription affordability has long existed in an organizational no-man’s-land. It is not fully clinical, yet its consequences are clinical. It is not purely financial, yet it drives downstream costs more reliably than many utilization controls.
As a result, it has been treated as a secondary concern, managed through benefit design assumptions and post-hoc member support, an approach that no longer aligns with reality.
A Medpac 2025 report states that 532,000 Medicare enrollees filled at least one prescription in 2023 with costs high enough to trigger catastrophic coverage, up from 33,000 in 2010. This is not a gradual trend; it is a structural shift that compresses risk into discrete moments where plans must act correctly the first time.
The specialty drug era has made these crises sudden and concentrated. When a patient leaves the pharmacy without medications in hand, the healthcare system loses control of the care trajectory.
A Policy Built for a System That Does Not Yet Exist
At its core, M3P is a payment-timing mechanism. It smooths out-of-pocket costs across the year rather than reducing them.
What demands scrutiny is the executional assumption embedded within it. The program presumes health plans can identify which members would benefit, reach them early enough to matter, and absorb the resulting complexity across billing, pharmacy coordination, and member support.
Early experience suggests this assumption does not hold universally. Participation has concentrated among beneficiaries who are already engaged, health literate, and managing expensive therapies.
Low uptake is not simply a matter of demand; it reflects an inability to identify and act on affordability pressure before it surfaces as a failed claim.
Three Leaders, One Gap: How Affordability Pressure Surfaces Too Late
For financial leaders, M3P changes cost recovery mechanics. Moving cost sharing from the point of sale to an extended horizon introduces uncertainty, requiring forecasting and reserves before outcomes are clear.
Operational leaders face parallel challenges. The program adds complexity across pharmacy interactions, enrollment workflows, and member support, even when participation remains limited.
Clinical leaders see downstream consequences. Cost-driven nonadherence does not announce itself; it surfaces later as disease progression and avoidable utilization.
Research from the Journal of the American Heart Association shows that missing anticoagulant doses for six months or longer increases stroke risk more than three-fold. JAMA Network Open survey data found that 20.2% of adults 65 and older reported cost-related nonadherence, with 8.5% going without food or heat to afford medications.
What unites these pressures is timing. Financial, operational, and clinical consequences now emerge earlier and with far less tolerance for delay than legacy governance models were designed to handle. Affordability is being addressed after it disrupts care, not before.
Same Plan, Different Pressure: Why Geography Shapes Affordability
Limited uptake is often blamed on beneficiary misunderstanding. That explanation is incomplete because it treats the problem as uniform when it is not.
Financial strain clusters by geography, therapy class, income stability, and disease burden. Two adjacent ZIP codes can experience the same formulary in fundamentally different ways. When organizations cannot distinguish between who might benefit in theory and who is experiencing pressure in practice, interventions default to scale rather than precision. The result is predictable: low response, high effort, limited impact.
That uneven pressure does not stop at the plan level; it shapes how and when patients access therapy.
When Affordability Pressure Becomes an Access Signal for Life Sciences
For manufacturers, M3P changes where and when affordability pressure shows up in the patient journey, turning it into an early access signal that alters access performance, early persistence, and forecasting for high‑cost Part D therapies.
For specialty oral agents and oncology drugs, large upfront out-of-pocket costs have historically driven early abandonment, particularly at the start of the year. By spreading liability into predictable monthly installments, M3P can reduce that initial shock even when benefit design remains unchanged. The result is not guaranteed uptake, but a measurable shift in the conditions under which patients say yes or walk away.
That shift creates a new access signal. Claims and plan-level reporting allow manufacturers to observe whether smoothing cost exposure increases initiation and short-term persistence relative to historical patterns. Differences in abandonment, reversals, and days on therapy between M3P participants and non-participants reveal demand elasticity that was previously masked by one-time cost spikes.
For example, manufacturers can track proportion of days covered (PDC) or medication possession ratio (MPR) for high‑cost Part D therapies, comparing M3P participants versus non‑participants to quantify how smoothing out‑of‑pocket costs improves early persistence and reduces early discontinuation.
Of course, any such analysis must respect HIPAA privacy rules and CMS data‑use constraints, relying on aggregated, de‑identified, or appropriately governed datasets rather than individual‑level patient information.
The strategic risk is that you cannot see how it changes behavior until after access patterns have already shifted. This shift in days‑on‑therapy interacts directly with the IRA‑driven Part D redesign and the Medicare Part D Manufacturer Discount Program starting in 2025, where improved adherence can increase manufacturer discount obligations in the initial and catastrophic phases while plans absorb more of the upfront cost.
Manufacturers that lack visibility into plan implementation, enrollment timing, and adherence dynamics face the same risk as plans: discovering access erosion only after net performance has already shifted.
For plans and manufacturers alike, the organizations that can translate affordability pressure into early, actionable signals will turn operational complexity into a durable competitive advantage.
The Real Lesson: Policy Cannot Outrun Infrastructure
M3P did not underperform because its intent was flawed. It underperformed because it assumed a level of operational intelligence that much of the system has not yet built.
Prescription affordability now sits at the center of financial performance, clinical outcomes, regulatory scrutiny, and member trust. When plans and manufacturers detect cost pressure only after a claim fails or a therapy is abandoned, they surrender control of outcomes that increasingly determine competitiveness in Medicare.
The organizations that will pull ahead are not those that redesign benefits or launch new support programs in isolation. They are the ones that treat affordability pressure as an early operational signal, translate it into targeted action, and measure impact before nonadherence and utilization shifts take hold.
The implication for executives is clear. Build the capability to see where prescription cost exposure concentrates and escalates, in time to intervene, or continue managing its consequences downstream. M3P did not fail. It revealed exactly where the system is exposed, at the moment patients decide whether care is affordable enough to continue.
